Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This could get very interesting.
Date Short Volume IPIX Total Volume Percent
2021-11-08 1,953,364 3,258,505 59.95%
Come on Brilacidin!
Database Lock Completed for Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for COVID-19
WAKEFIELD, MA / November 3, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that the Company has received confirmation that hard lock of the database was completed for its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Statistical analysis is underway, with topline results for the trial anticipated to be reported during the week of November 8, 2021.
Plus - wolf(e) = apex land predator / Mako = apex sea predator
This fictional Facebook character will be invested.
Hold tight and be right.
Go Leo & IPIX
In related news, the Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin. In addition to Brilacidin’s antiviral profile, Brilacidin’s immunomodulatory and anti-inflammatory properties may be particularly beneficial in treating COVID-19 in hospitalized patients.
NEWS! Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin’s Broad-Spectrum Antiviral Properties
WAKEFIELD, MA / September 23, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897), as well as related news.
Based on information received from the data management and biostatistics vendors, study unblinding, analysis of the unblinded data and release of topline study results for the Brilacidin COVID-19 trial is anticipated to occur in mid-to-late October. The Company looks forward to the data to learn if Brilacidin’s multiple properties translate into meaningful clinical results, given the unmet need for COVID-19 therapeutics and ongoing pandemic.
In related news, the Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin. In addition to Brilacidin’s antiviral profile, Brilacidin’s immunomodulatory and anti-inflammatory properties may be particularly beneficial in treating COVID-19 in hospitalized patients.
For more details on the Company's Expanded Access policy, please visit:
https://www.ipharminc.com/expanded-access-and-compassionate-use
Brilacidin in vitro antiviral research remains ongoing at multiple universities. New preliminary data from one academic laboratory show Brilacidin is active against adenoviruses—a non-enveloped virus—complementing earlier data showing potent Brilacidin inhibition of different strains of coronaviruses, alphaviruses and bunyaviruses (enveloped viruses). A paper from this lab on Brilacidin’s broad-spectrum antiviral effect in multiple virus families is being prepared. Separate scientific papers also are underway from two other academic research groups supporting Brilacidin’s antiviral properties and providing insight into Brilacidin’s mechanisms of action.
About Brilacidin and COVID-19
Very well thought out.... I also believe that finding a manufacturing partner will not be a problem. If there is money, they will come.
Go Leo & IPIX!
Another awesome post!
Go Leo & IPIX!
Way too go MackG! Great post. Hopefully Brilacidin can get too market and get the world back too normal.
Go Leo & IPiX!
Great post JFM!
Empiricst1, my wife and I chose not to have children's and therefore I have no opinion what people should do with their children. It is none of my business.
Go Leo & IPIX!
I will not be taking a vaccine anytime soon. Unfortunately Canada will be enforcing the vaccine passport so if I want to travel out of the country I will eventually have to take it. I see holding out for at least a couple of more years before I am forced.
I spend a lot of time, energy, money and make sacrifices in attempts to stay metabolically healthy. I am not a drain on the health system and it pisses me off that my freedom is being taken away. I believe that everyone should have the right to do what they feel is best for themselves...
I would however take a therapeutic like Brilacidin if proven effective. We already know it is safe...
Go Leo & IPIX!
You’re firing on all cylinders tonight!!
Nice find! I hope Brilacidin ends up on this list… that could be enormous for Leo and ultimately us.
Go Leo & IPIX!
Great post JFM and Hungry_Ghost!
I completely disagree for all of the reasons I posted yesterday and I think there was a lot of new information within that article. I believe it was very telling and we should have a better understanding of the situation in the coming weeks/months.
I am looking forward to see the final results.
yours truly, Yeehaw!
Go Leo & IPIX!
I agree, I thought it was very informative.
Go Leo & IPIX!
Great, thanks for the heads up PJ007!
Go Leo & IPIX!
What is a Bunyaviridae you ask? See below.
Bunyaviridae
The Bunyaviridae are a very large family of single-strand, enveloped RNA viruses (more than 300 viruses) and consists of five genera of viruses: Orthobunyavirus, Phlebovirus, Nairovirus, Hantavirus, and Tospovirus (Tospoviruses infect only plants). They are found in and transmitted by arthropods (e.g. mosquitoes, ticks, sand flies) and rodents, and can occasionally infect humans. Several viruses of the Bunyaviridae virus family can produce mild to severe disease in human, in animals, and sometimes in both. This is the base for the requirements of handling some of these viruses in high containment (Biosafety Level 3 or even Biosafety level 4).
https://www.cdc.gov/vhf/virus-families/bunyaviridae.html
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs.
1.6. Defensins against SARS-CoV
The lectin-like human a defensin 5 (HD5) and HD6 peptides protect intestinal infections. Lectins are proteins or glycoproteins that specifically bind to carbohydrates present on the glycoproteins surface. 2019-nCoV S-proteins and its intestinal receptor ACE2 both are glycosylated proteins. HD5 binds to the ligand-binding domain (LBD) of ACE2 glycoproteins and masks its availability to enter the 2019-nCoV virus (Wang et al., 2019). This interruption between viral glycoproteins and cellular receptors activates the adaptive immune antigen-presenting phagocytes cells and interferes with nuclear enzymes that prevent viral cellular replication (Park et al., 2018). Human neutrophil peptide-4, bovine beta-defensin 1, HD5, HD6, rat neutrophil peptide 1 (RNP-1), RNP-2, chicken avian beta-defensin 5 (AvBD5), AvBD6, and channel catfish beta-defensin peptide have the antiviral activity against the Middle East Respiratory Syndrome Coronavirus [3]. HNP1-6, HD5-6, and HBD2-3 defensins remove the viruses by getting in the way of viral entry, membrane destabilisation, immune-modulating, downregulating receptors and ligands such as ACE2, CD4, CCR6 CXCR4, CXCL & CXCL5, lysosome fusion, inhibiting essential proteases, central dogma enzymes, and post assembly of virion particles (Park et al., 2018 [37]; Chang et al., 2005; [70].
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs. Dalbavancin, Telavancin, Oritavanci, and Roflumilast are other Brilacidin like drugs used for MERS, SARS, and SARS-CoV2 viral inhibitions [71]. Rhesus macaque's leukocytes express ?-defensin1 (RTD-1) and RTD-2 antimicrobial peptides in response to viral infections. HD5-6, HNP1-6, HBD2-6, and retrocyclin-2 inactivate the various enveloped and non-enveloped virion particles by interrupting virus pre and post-entry steps, chemokines, and cytokines immunomodulation, chemotaxis of immune cells [72].
https://www.sciencedirect.com/science/article/pii/S0882401021002023
Brilacidin lab results against alphaviruses are to be provided, this July, in an Oral Presentation at the American Society of Virology’s 2021 annual conference. Brilacidin lab results in Human Coronaviruses (H-CoVs) (OC43, 229E, NL63) are being prepared for peer-review submission.
With enrollment in the Company’s Phase 2 trial of Brilacidin for treatment of COVID-19 proceeding toward completion and release of topline results, testing of Brilacidin at independent labs against multiple viruses is ongoing. Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs.
There is some very strong language in this release.
Go Leo & IPIX!
Journal Article on Defensins Highlights Brilacidin’s Potential as a Broad Spectrum Antiviral
Innovation wanted to bring to the attention of shareholders a recent review article that supports defensins as a source of potential therapeutics against viral infections.
Solanki SS, Singh P, Kashyap P, Sansi MS, Ali SA.
“Promising role of defensins peptides as therapeutics to combat against viral infection.”
Microb Pathog. 2021 Apr 29:104930. doi: 10.1016/j.micpath.2021.104930. Epub ahead of print. PMID: 33933603.
https://www.sciencedirect.com/science/article/pii/S0882401021002023
As the article conveys, newer mechanistic insights are elucidating the intrinsic and multi-faceted abilities of defensins—a type of small antimicrobial peptide—to confer protection against many types of viruses.
Brilacidin, a defensin-mimetic designed and optimized to capture the biological properties of naturally occurring defensins, was highlighted in the article:
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs.
With enrollment in the Company’s Phase 2 trial of Brilacidin for treatment of COVID-19 proceeding toward completion and release of topline results, testing of Brilacidin at independent labs against multiple viruses is ongoing. Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.
Brilacidin lab results against alphaviruses are to be provided, this July, in an Oral Presentation at the American Society of Virology’s 2021 annual conference. Brilacidin lab results in Human Coronaviruses (H-CoVs) (OC43, 229E, NL63) are being prepared for peer-review submission.
Great post JFM!
How many people are dying of lung cancer from smoking - approximately 130,00 each year in US? Alcoholism - approximately 95,000 each year in US? Obesity - approximately 300,000 each year in the US? We don't hear about that in the media, why you ask, because it will not convince those participating in these behaviors to stop.
I am not trying to minimize your comments I am simply pointing out that whatever causes the most fear gets the biggest budget. At your expense might I add.
I hope Brilacidin can work against COVID and its variants and I hope it is soon.
Go Leo & IPIX!
I don't have that fear. I believe the media/governments will continue to make COVID an excuse for everything over the next several years. It is a pretty huge excuse to generate lots of spending.
Agreed! Unfortunately this not happening as fast as I would like but Brilacidin keeps making positive progress which is all I ever want.
Brilacidin is a serious contender for the treatment COVID and its variants and I can't wait for the final results.
Go Leo & IPIX!
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
• >60 patients have been randomized in the Company’s ~120-patient Phase 2 COVID-19 clinical trial
• With COVID-19 cases rising worldwide as the coronavirus continues to mutate, the need is greater than ever to develop novel broad spectrum antivirals of the future
WAKEFIELD, MA – April 28, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897).
Brilacidin is the only non-peptidic defensin-mimetic drug candidate in the world currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19. Additionally, Brilacidin has shown potent inhibition in vitro against different strains of coronaviruses and alphaviruses (with lab testing against other virus families also underway), supporting Brilacidin’s potential to be developed as a broad spectrum antiviral.
“Achieving over 50 percent trial enrollment represents an important milestone as we advance Brilacidin for treatment of COVID-19,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We are hopeful Brilacidin will emerge not only as an effective COVID-19 therapeutic, but also as a desperately needed broad spectrum antiviral. With the world experiencing a record number of new COVID-19 cases, including nearly 1 million new infections in India across a 3-day period, we remain dedicated to bringing to market a novel antiviral to help ease patient suffering. We look forward to completing our COVID-19 clinical trial and releasing topline results.”
Linked below are recent articles published in the journal Nature. Both reinforce the need for developing novel antiviral drugs, such as Brilacidin, to help address the current COVID-19 crisis, as well as to be prepared to confront future pandemics.
• Funders, now is the time to invest big in COVID drugs (nature.com): Vaccine development has been a resounding success. But the medicine cabinet should have been better stocked.
• The race for antiviral drugs to beat COVID — and the next pandemic (nature.com): Despite dire warnings, a stockpile of ready compounds to fight viral pandemics was sorely lacking. Can drugmakers finally do the right thing?
About Brilacidin and COVID-19
Innovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and currently is enrolling patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Upon recently completing a scheduled review of interim safety data from the trial, an independent Data Monitoring Committee (DMC) recommended increasing the dosing regimen of Brilacidin from 3 days to 5 days of treatment, which may maximize therapeutic benefits and provide a comparison with 5-day remdesivir (Veklury™), currently the only FDA-approved treatment for COVID-19. The annual global antiviral drug market is estimated to reach $44 billion by 2026.
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
• >60 patients have been randomized in the Company’s ~120-patient Phase 2 COVID-19 clinical trial
• With COVID-19 cases rising worldwide as the coronavirus continues to mutate, the need is greater than ever to develop novel broad spectrum antivirals of the future
WAKEFIELD, MA – April 28, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897).
Brilacidin is the only non-peptidic defensin-mimetic drug candidate in the world currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19. Additionally, Brilacidin has shown potent inhibition in vitro against different strains of coronaviruses and alphaviruses (with lab testing against other virus families also underway), supporting Brilacidin’s potential to be developed as a broad spectrum antiviral.
“Achieving over 50 percent trial enrollment represents an important milestone as we advance Brilacidin for treatment of COVID-19,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We are hopeful Brilacidin will emerge not only as an effective COVID-19 therapeutic, but also as a desperately needed broad spectrum antiviral. With the world experiencing a record number of new COVID-19 cases, including nearly 1 million new infections in India across a 3-day period, we remain dedicated to bringing to market a novel antiviral to help ease patient suffering. We look forward to completing our COVID-19 clinical trial and releasing topline results.”
Linked below are recent articles published in the journal Nature. Both reinforce the need for developing novel antiviral drugs, such as Brilacidin, to help address the current COVID-19 crisis, as well as to be prepared to confront future pandemics.
• Funders, now is the time to invest big in COVID drugs (nature.com): Vaccine development has been a resounding success. But the medicine cabinet should have been better stocked.
• The race for antiviral drugs to beat COVID — and the next pandemic (nature.com): Despite dire warnings, a stockpile of ready compounds to fight viral pandemics was sorely lacking. Can drugmakers finally do the right thing?
About Brilacidin and COVID-19
Innovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and currently is enrolling patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Upon recently completing a scheduled review of interim safety data from the trial, an independent Data Monitoring Committee (DMC) recommended increasing the dosing regimen of Brilacidin from 3 days to 5 days of treatment, which may maximize therapeutic benefits and provide a comparison with 5-day remdesivir (Veklury™), currently the only FDA-approved treatment for COVID-19. The annual global antiviral drug market is estimated to reach $44 billion by 2026.
I live in Ontario and we are currently in a lockdown until at least May 20th and it will probably get extended because that is before our long weekend. They were talking about implementing a curfew. Ugh! This has been at least our fourth/fifth lockdown since it got here in 2020.
The world needs Brilacidin to work and work fast...
Go Leo - Make this happen!
Agreed, great post!
Great post JFM (in its entirety).
Post sites article in Nature (journal) that states several "substances" with very low SI showed "little" effect on virus replication OR showed SEVERE ADVERSE EFFECT in human patients....
1. WHY WOULDN"T THEY SHOW "LITTLE" effect...THEY HAD VERY LOW SI SCORES!!! IN FACT, All these "Substances" COMBINED did not match BRILACIDIN'S SI SCORE *426*. TO COMPARE THESE SUBSTANCES TO OR ANY SUBSTANCE in competition with BRILACIDIN...the substance being compared (which there are NONE) would be "SI" Score of 426...THERE ARE NO OTHERS! So, the comparative statement is comparing rotten apples to juicy oranges.
2. AGAIN...BRILACIN's SI's 426 SCORE is greater than ALL THOSE SUBSTANCES SI SCORE COMBINED and they showed "Little effect", therefore it is reasonable to expect Brilacidin, with 10X SI score of substances cited,...to show SIGNIFICANTLY MORE EFFECT on Covid viral suppression.
3. SAE COMPARISON? as is noted in quote...those OTHER SUBSTANCES "...led to SAE (severe adverse events and side effects) in human patients."...OK...but BRILACIDIN throughout PHASE II Clinical Trials for 5 Different Indications...BRILACIDIN has NEVER CAUSED a single SAE.
So what these "other" substances do it totally irrelevant to Brilacidin.
Quote:
"...several substances like Remdesivir, Lopinavir and Chloroquine were reported to repress viral replication in vitro. However, these compounds showed little effect on virus replication or led to severe adverse side effects in human patients." Bottom line: is that the
in vitro assays in cells did not predict clinical behavior.
Conclusion:
SUBSTANCES WITH Small SI SCORES showed small SUPRESSION of VIRAL SUPPRESSION in Clinical Trials...therefore Substances (Brilacidin) with EXTREMELY HIGH (HIGHEST) SI SCORE OF POTENTIAL THERAPEUTICS ... will likely demonstrate in Clinical Trials EXTREMELY HIGH VIRAL SUPPRESSION in current clinical trials...compared to the substances sited.
Thank you for providing a post to further demonstrate the GREAT POTENTIAL of BRILACIDIN vs. Covid-19 IMO soon to be demonstrated in the current Clinical Trials!
Great post! Thanks
Go Leo & IPIX!
Loanranger...both you and SUN refer to SE (side effects) of Brilacidin in clinical trials...and SUN asserts they occur 50% of the time...but neither of you can not come up with "one" CITED IN FDA CLINICAL TRIALS for the 5 separate indications involving Brilacidin prior Clinical Trials.
So are you saying there were "SE" cited by FDA in some or all of the Clinical Trials (Phase I anc Phase II)? if so WHAT WERE THEY and if so Show how they occurred in over 50% of the candidate...
You can't, because Brilacidin SE were never asserted or noted by the FDA...There were NO SE asserted by FDA and the statement and inference is totally false!
Courtesy of JFM!
There have been voluminous posts admitting to the "total confusion" regarding Leo's stock positions and dispositions, involving Class A stock, Class B stock, including sales, exchanges, conversions etc.
From that "cloudiness" there seems to be an inference that their personal confusion and lack of their "personal" understanding of what they are reading justifies the raises of issues and suspicion of "nefarious conduct" by Leo...
I checked with a CPA from a Public Accounting firm...the comment to me was "Its a nothing burger" ... the questions asked reflect a basic lack of understanding of public accounting 101. "Nothing improper there...just ignorance of those questioning...which if they asked the SEC (and if the party even received a response), the party questioning would display their ignorance with their questions and receive the same response."
All this commentary, even though IPIX has Public Accounting firm, and SEC attorneys who review regulatory filings and clears them prior to filing!
Great post JFM and thanks!
Release!
Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
WAKEFIELD, MA – April 14, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company’s defensin-mimetic drug candidate, was featured in the “Mason Science Series: Rising to the National and International COVID-19 Challenge,” a presentation of George Mason University.
The presentation covers the latest research of Dr. Aarthi Narayanan, a faculty member in George Mason’s National Center for Biodefense and Infectious Diseases, and her team’s (and associated teams) efforts, which are geared towards the development of therapeutics and vaccines against SARS-CoV-2, including Brilacidin. A video of Dr. Narayanan’s presentation can be accessed at the link below. Discussion of Brilacidin begins at approximately the 40-minute mark.
• Mason Science Series: Rising to the National and International COVID-19 Challenge - YouTube
Dr. Narayanan has been leading ongoing research assessing Brilacidin’s broad spectrum antiviral potential, with preliminary in vitro data showing Brilacidin potently inhibits both coronaviruses and alphaviruses. As previously released, these data will serve as the basis for an Oral Presentation on Brilacidin’s antiviral properties to be delivered at the American Society of Virology’s 40th Annual Meeting (ASV 2021), taking place July 19-23, 2021.
Variants of the SARS-CoV-2 virus continue to pose a significant challenge in the COVID-19 pandemic. Today, the B.1.1.7 variant, first discovered in the United Kingdom, is the most common variant in the U.S., according to Centers for Disease Control and Prevention (CDC) Director, Dr. Rochelle Walensky. Due to a potential lessened therapeutic effect against variants, monoclonal antibody treatments have been called into question. Eli Lilly, for example, recently stopped supplying bamlanivimab as a solo therapy for treatment of COVID-19. Variants are showing a similar ability to reduce the effectiveness of COVID-19 vaccines, with safety concerns associated with vector-based vaccines surfacing.
To help satisfy a large unmet need in the antiviral therapeutics area, the Company is developing Brilacidin as a potential novel broad spectrum antiviral drug.
I really like this press release!
If Brilacidin goes on to realize its promise as a broad spectrum antiviral, the potential benefits to patients and shareholders for this drug would likely be greater than I or anyone could have ever imagined.”
http://www.ipharminc.com/press-release/2021/4/7/innovation-pharma-announces-brilacidin-abstract-accepted-for-oral-presentation-at-the-american-society-for-virologys-annual-meeting
Go Leo & IPIX!
IMO...trials will be expedited and be over quickly...and done where ever they can be completed the fastest. If we get the results commensurate with the GMU RBL results...it opens up ALL Virus research, development and associated opportunities...IMO ALL OPPORTUNITIES !!!
Reading through all the PRs...and putting them together...IMO interest by the scientific/medical community in Brilacidin is beyond Covid-19 and...is into the "Holy Grail" aspect of Brilacidin functionality...(even before current CT is over).
TIAB speculated: “MERS and SARS and other coronaviruses might be B targets. It was hinted there was work being done."
IMO...it’s MORE THAN A HINT!
This reference in PR AGAIN to RBL continued Testing (in lab other than GMU) with focus on Pan-Coronaviruses...which is independent of the IPIX, HAS POPPED UP AGAIN...IMO...LEO is indicating at least one highly focused RBL is continuing to test Brilacidin against ALL VIRUSES.
These independent RBLs do not report to the company about their "findings", but they do publish independent "Peer Reviewed" articles about those findings and the results of a company's compounds (in our case...Brilacidin) that they study and test.
...They also seek and receive "grants" for themselves under generic titles as in "Compounds to treat all Pan-coronaviruses"... (not overtly stating "Brilacidin" as their target). These Grants are separate and apart from the company's (they want all the money, control, and bragging rights) ...from CDC, BARDA, NIH, DOD etc...
Last PR appeared to indicate...BRILACIDIN...is in the crosshairs of a specialized RBL focusing on Pan-coronaviruses. We will not know when Brilacidin testing on other Pan-coronaviruses will be complete, nor when results ready for public consumption...but IMO as an effective and broad range antiviral/antibacterial (which DeGrado has always contended), Brilacidin/Covid-19 challenge and success, alone becomes chump change for the Brilacidin horizon.
Those shorts/impatient will likely disparage the above ...but "investors" will be patient and savor the opportunity. IMO Investors will receive a multiple of MORE for what they even imagined...if trial results confirm DeGrado's belief...I am more confident in DeGrado's judgment than uninformed posters...
Great post Justfactsmam!
Good Friday, April 2 2021
Go Leo & IPIX!